PPIs Prevent Aspirin-Induced Gastrointestinal Bleeding Better than H2RAs. A Systematic Review and Meta-analysis

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Background:

• Low-dose aspirin (LDA) is widely used for its analgesic and anti-platelet effects.
• LDA use is associated with a significant risk of gastrointestinal (GI) bleeding and ulcer formation.
• Histamine-2 receptor antagonists (H2RAs) and proton-pump inhibitors (PPIs) are commonly used to prevent these GI complications.

Purpose of the Study:

• To compare the efficacy of H2RAs and PPIs in preventing GI bleeding and ulcer formation in patients on chronic LDA therapy.
• To determine which class of medication offers superior protection against LDA-induced GI adverse events.

Main Methods:

• A systematic literature search was conducted on PubMed, Embase, and Cochrane Central Register of Controlled Trials up to September 30, 2016.
• Included were randomized controlled trials and observational studies comparing H2RAs and PPIs for GI protection in LDA users.
• Data from nine studies on GI bleeding and eight on ulcer formation, involving 1,879 patients, were meta-analyzed.

Main Results:

• H2RAs were found to be less effective than PPIs in preventing LDA-related GI bleeding (OR=2.102).
• H2RAs also showed lower efficacy in preventing LDA-related ulcer formation compared to PPIs (OR=2.257).
• Statistical analysis indicated a significant difference in protective effects between the two drug classes.

Conclusions:

• PPIs demonstrate superior effectiveness in preventing both GI bleeding and ulcer formation associated with chronic LDA use.
• The findings suggest that PPIs should be preferentially prescribed over H2RAs for GI protection in patients taking LDA, provided they are tolerated.